Boehringer Ingelheim Pharmaceuticals has the exclusive rights to manufacture Pradaxa (dabigatran) until February 2018. After the first patent for the medication expires, various other companies may manufacture a generic Pradaxa product. However, lawsuits or other patents for specific uses of the drug may delay the manufacturing of a generic product. Although dabigatran is the "generic name" for Pradaxa, it is not a generic version of it.
Pradaxa® (dabigatran etexilate mesylate) is a prescription anticoagulant medication used to prevent strokes and blood clots in people with an irregular heart rhythm known as atrial fibrillation. It belongs to a group of medications known as direct thrombin inhibitors.
Pradaxa is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. There are no generic versions of Pradaxa available at this time.
The first patent for Pradaxa is currently set to expire in February 2018. This is the earliest predictable date that a generic version could become available.
However, there are other circumstances that could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Pradaxa uses. It is usually quite difficult to predict when exactly a generic version of any medication may become available.
No -- dabigatran is the active ingredient in Pradaxa, but it is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.